Live cell therapy clinical trial in New Zealand for diabetics
Living Cell Technologies receives New Zealand’s Health Minister?s approval to start leading edge live cell therapy clinical trial in New Zealand for Diabetes patients. – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) announced that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell?, LCT’s lead product candidate for the treatment of insulin dependent (Type 1) diabetes.